Variabilidad farmacocinética en pacientes con trasplante renal tratados con ciclosporina evaluación de variantes genéticas como covariables
FJ Corvalán Nazal - 2017 - repositorio.udec.cl
Ciclosporina (CsA) es un fármaco inmunosupresor utilizado para prevenir el rechazo de
órganos en pacientes trasplantados. Sin embargo, esta droga se caracteriza por poseer un …
órganos en pacientes trasplantados. Sin embargo, esta droga se caracteriza por poseer un …
[HTML][HTML] Análisis farmacogenético de la cinética de absorción de ciclosporina en una población española de pacientes trasplantados cardíacos
BI Tejera, MDA Rubio, J Martínez-Moreno… - Farmacia …, 2009 - Elsevier
Objetivo Determinar el papel de polimorfismos de nucleótido único localizados en los genes
MDR1, CYP3A4 y CYP3A5 sobre la cinética de absorción de ciclosporina en pacientes …
MDR1, CYP3A4 y CYP3A5 sobre la cinética de absorción de ciclosporina en pacientes …
Explaining variability in ciclosporin exposure in adult kidney transplant recipients
RR Press, BA Ploeger, J Den Hartigh… - European journal of …, 2010 - Springer
Abstract Purpose Optimal ciclosporin A (CsA) exposure in kidney transplant recipients is
difficult to attain because of variability in CsA pharmacokinetics. A better understanding of …
difficult to attain because of variability in CsA pharmacokinetics. A better understanding of …
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1 …
DA Hesselink, T van Gelder… - Clinical …, 2004 - Wiley Online Library
Objective Our objective was to determine the relationship between single nucleotide
polymorphisms (SNPs) in the multidrug resistance 1 (MDR‐1) gene and the cytochrome …
polymorphisms (SNPs) in the multidrug resistance 1 (MDR‐1) gene and the cytochrome …
CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation
D Anglicheau, E Thervet, I Etienne… - Clinical …, 2004 - Wiley Online Library
Background The immunosuppressive drug cyclosporine (INN, ciclosporin), whose
pharmacokinetic characteristics vary greatly among individuals, is a substrate for …
pharmacokinetic characteristics vary greatly among individuals, is a substrate for …
CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics
J Song, MG Kim, B Choi, NY Han… - Annals of …, 2012 - journals.sagepub.com
BACKGROUND: Cyclosporine is often used to prevent allograft rejection in renal transplant
recipients. However, cyclosporine has a narrow therapeutic window and large variability in …
recipients. However, cyclosporine has a narrow therapeutic window and large variability in …
[HTML][HTML] Effect of multidrug-resistant 1 (MDR1) and CYP3A4* 1B polymorphisms on cyclosporine-based immunosuppressive therapy in renal transplant patients
MJ Kotowski, A Bogacz… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Immunosuppressive drugs such as cyclosporine A (CsA) are characterized by a
narrow therapeutic range and high interindividual pharmacokinetic variations. Therefore, the …
narrow therapeutic range and high interindividual pharmacokinetic variations. Therefore, the …
Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients
Advances in immunosuppressive therapy allowed renal transplantation to become the
treatment of choice for suitable candidates with (end stage renal disease) ESRD. The post …
treatment of choice for suitable candidates with (end stage renal disease) ESRD. The post …
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
S Contreras-Castillo, A Plaza, J Stojanova… - Frontiers in …, 2021 - frontiersin.org
Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
[PDF][PDF] Análisis farmacogenético de la ciclosporina en relación a los factores farmacocinéticos-farmacodinámicos y la incidencia de rechazo agudo tras el trasplante …
B Isla Tejera - 2008 - digibug.ugr.es
Introducción: El trasplante cardíaco continúa siendo el tratamiento definitivo en pacientes
con insuficiencia cardíaca terminal. La ciclosporina (CsA) es uno de los fármacos más …
con insuficiencia cardíaca terminal. La ciclosporina (CsA) es uno de los fármacos más …